Preliminary results and ongoing trials for aGVHD/SR-aGVHD treatment
| Investigational agent . | Day 28 ORR, % . | Ongoing trials . |
|---|---|---|
| aGVHD (high risk) | ||
| Itolizumab | 65 | NCT05263999 |
| IL-22 | 70 | NCT02406651 |
| Natalizumab | 57 | NCT02133924 |
| AAT | 5 | NCT04167514 |
| RIP1 | — | Planned |
| SR-aGVHD | ||
| Neihulizumab | 69 | NCT03327857 |
| Apraglutide | — | NCT05415410 |
| BET inhibitor | — | NCT04910152 |
| hCG/EGF | 62 | NCT02525029 |
| FMT | 71.4∗ | NCT03359980, NCT03812705 |
| Investigational agent . | Day 28 ORR, % . | Ongoing trials . |
|---|---|---|
| aGVHD (high risk) | ||
| Itolizumab | 65 | NCT05263999 |
| IL-22 | 70 | NCT02406651 |
| Natalizumab | 57 | NCT02133924 |
| AAT | 5 | NCT04167514 |
| RIP1 | — | Planned |
| SR-aGVHD | ||
| Neihulizumab | 69 | NCT03327857 |
| Apraglutide | — | NCT05415410 |
| BET inhibitor | — | NCT04910152 |
| hCG/EGF | 62 | NCT02525029 |
| FMT | 71.4∗ | NCT03359980, NCT03812705 |
Dashes denote that the data is not available. BET, bromodomain and extraterminal domain; EGF, epidermal growth factor; FMT, fecal microbiome transplant; hCG, human chorionic gonadotropin; RIP1, receptor-interactive protein kinase 1.
In combination with ruxolitinib.